Research programme: fatty acid amide hydrolase inhibitors - Amgen
Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Amgen
- Class Heterocyclic bicyclo compounds; Imidazolidines; Piperidines; Pyridines
- Mechanism of Action Fatty acid amide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported CNS disorders; Inflammation; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in CNS-disorders in USA
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in USA
- 16 Jul 2016 No recent reports of development identified for research development in Pain in USA